^
Association details:
Biomarker:No biomarker
Cancer:Soft Tissue Sarcoma
Drug:Votrient (pazopanib) (Multi-tyrosine kinase inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
VOTRIENT is a kinase inhibitor indicated for the treatment of adults with:...advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
03/29/2022
Excerpt:
Soft Tissue Sarcoma...Other Recommended Regimens...Gemcitabine and pazopanib
Secondary therapy:
gemcitabine
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
10/30/2020
Excerpt:
Soft Tissue Sarcoma: Preferred regimens…Pazopanib...
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Title:

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Excerpt:
Summary of recommendations...Pazopanib is an option in non-adipogenic STS [I, B].
DOI:
10.1093/annonc/mdy310